Neurology-Neuroimmunology & Neuroinflammation

Article	Citations
Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes	285
Guillain-Barré syndrome related to COVID-19 infection	267
Guillain-Barré syndrome: The first documented COVID-19–triggered autoimmune neurologic disease	183
Clinical approach to the diagnosis of autoimmune encephalitis in the pediatric patient	170
International multicenter examination of MOG antibody assays	161
COVID-19-related acute necrotizing encephalopathy with brain stem involvement in a patient with aplastic anemia	151
Acute disseminated encephalomyelitis after SARS-CoV-2 infection	150
COVID-19 outcomes in MS	127
Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology	111
Anti–SARS-CoV-2 antibodies in the CSF, blood-brain barrier dysfunction, and neurological outcome	101
Peripheral Neuropathy Evaluations of Patients With Prolonged Long COVID	100
COVID-19-associated acute necrotizing myelitis	99
Neurologic syndromes related to anti-GAD65	98
COVID-19 and MS disease-modifying therapies	84
Guillain-Barré syndrome related to SARS-CoV-2 infection	81
Acute Disseminated Encephalomyelitis and Acute Hemorrhagic Leukoencephalitis Following COVID-19	78
Neurosarcoidosis	76
Risk of COVID-19 infection in MS and neuromyelitis optica spectrum disorders	71
COVID-19 Among Patients With Multiple Sclerosis	66
BMI and low vitamin D are causal factors for multiple sclerosis	66
Clinical and imaging features of children with autoimmune encephalitis and MOG antibodies	65
Diagnostic yield of commercial immunodots to diagnose paraneoplastic neurologic syndromes	65
Epidemiology of paraneoplastic neurologic syndromes and autoimmune encephalitides in France	64
Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19	64
International Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis	63

Single-cell RNA-seq analysis of human CSF microglia and myeloid cells in neuroinflammation	63
Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG–Associated Disease and Neuromyelitis Optica Spectrum Disorders	63
COVID-19 infection in a patient with multiple sclerosis treated with fingolimod	60
Increased CSF levels of IL-1β, IL-6, and ACE in SARS-CoV-2–associated encephalitis	60
COVID-19-associated ophthalmoparesis and hypothalamic involvement	58
Overlapping central and peripheral nervous system syndromes in MOG antibody–associated disorders	57
Serum biomarkers in myelin oligodendrocyte glycoprotein antibody–associated disease	55
Rituximab, MS, and pregnancy	55
Rituximab Treatment and Long-term Outcome of Patients With Autoimmune Encephalitis	55
Monoclonal antibody treatment during pregnancy and/or lactation in women with MS or neuromyelitis optica spectrum disorder	53
COVID-19—White matter and globus pallidum lesions	53
COVID-19 Severity in Multiple Sclerosis	53
Clinical and MRI phenotypes of sarcoidosis-associated myelopathy	53
CNS inflammatory vasculopathy with antimyelin oligodendrocyte glycoprotein antibodies in COVID-19	51
Motor cortex transcriptome reveals microglial key events in amyotrophic lateral sclerosis	50
Presentations and mechanisms of CNS disorders related to COVID-19	49
Clinical spectrum and diagnostic pitfalls of neurologic syndromes with Ri antibodies	48
Clinical significance of Kelch-like protein 11 antibodies	48
Frequency of myelin oligodendrocyte glycoprotein antibody in multiple sclerosis	47
Dysregulation of the Adaptive Immune System in Patients With Early-Stage Parkinson Disease	45
Retinal Optical Coherence Tomography in Neuromyelitis Optica	45
Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?	43
Long-term efficacy of mycophenolate mofetil in myelin oligodendrocyte glycoprotein antibody-associated disorders	43
Immune profiling of plasma-derived extracellular vesicles identifies Parkinson disease	42
Plasma Markers of Neurologic Injury and Inflammation in People With Self-Reported Neurologic Postacute Sequelae of SARS-CoV-2 Infection	41
Myelin Oligodendrocyte Glycoprotein-Immunoglobulin G in the CSF	41
Serum neurofilament light chain is a useful biomarker in pediatric multiple sclerosis	41
Long-term Functional Outcomes and Relapse of Anti-NMDA Receptor Encephalitis	40
Slowly Expanding Lesions Predict 9-Year Multiple Sclerosis Disease Progression	40
Clinical and Prognostic Value of Immunogenetic Characteristics in Anti-LGI1 Encephalitis	40
Pain, Depression, and Quality of Life in Neuromyelitis Optica Spectrum Disorder	40
Anti-IGLON5 disease	40
IgG4-Mediated Neurologic Autoimmunities	40
New BBB Model Reveals That IL-6 Blockade Suppressed the BBB Disorder, Preventing Onset of NMOSD	40
Anti-CD20 therapies and pregnancy in neuroimmunologic disorders	39
HLA association in MOG-IgG– and AQP4-IgG–related disorders of the CNS in the Dutch population	38
Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis	38
Effect of Ocrelizumab in Blood Leukocytes of Patients With Primary Progressive MS	38
Altered fovea in AQP4-IgG–seropositive neuromyelitis optica spectrum disorders	37
Pediatric autoimmune encephalitis	37
Treatment and outcome of aquaporin-4 antibody–positive NMOSD	35
The Bruton tyrosine kinase inhibitor ibrutinib improves anti-MAG antibody polyneuropathy	35
Hypogammaglobulinemia and Infections in Patients With Multiple Sclerosis Treated With Rituximab	35
Impact of Disease-Modifying Treatments of Multiple Sclerosis on Anti–SARS-CoV-2 Antibodies	34
Chitinases and chitinase-like proteins as biomarkers in neurologic disorders	34
Encephalopathies Associated With Severe COVID-19 Present Neurovascular Unit Alterations Without Evidence for Strong Neuroinflammation	33
COVID-19 in MS	33
Discontinuation of Immunosuppressive Therapy in Patients With Neuromyelitis Optica Spectrum Disorder With Aquaporin-4 Antibodies	33
Plasma Biomarkers of Neuropathogenesis in Hospitalized Patients With COVID-19 and Those With Postacute Sequelae of SARS-CoV-2 Infection	33
Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis	31

Paraneoplastic cerebellar ataxia and antibodies to metabotropic glutamate receptor 2	31
Gene-Environment Interactions in Multiple Sclerosis	31
Anti-IgLON5 Disease	31
Leveraging Visual Outcome Measures to Advance Therapy Development in Neuroimmunologic Disorders	31
Recent cannabis use in HIV is associated with reduced inflammatory markers in CSF and blood	31
Seizure-related 6 homolog like 2 autoimmunity	30
Risk of Getting COVID-19 in People With Multiple Sclerosis	30
Choroid Plexus Volume in Multiple Sclerosis vs Neuromyelitis Optica Spectrum Disorder	30
Inflammatory profiles relate to survival in subtypes of amyotrophic lateral sclerosis	30
Cladribine vs other drugs in MS	30
MS optic neuritis-induced long-term structural changes within the visual pathway	30
Pregnancy outcomes in anti-NMDA receptor encephalitis	30
Increased Serum Neurofilament Light and Thin Ganglion Cell–Inner Plexiform Layer Are Additive Risk Factors for Disease Activity in Early Multiple Sclerosis	29
Transfer of monoclonal antibodies into breastmilk in neurologic and non-neurologic diseases	29
Clinical utility of AQP4-IgG titers and measures of complement-mediated cell killing in NMOSD	29
Microglia Activation in Basal Ganglia Is a Late Event in Huntington Disease Pathophysiology	29
Incidence and Impact of COVID-19 in MS	28
Targeting B Cells to Modify MS, NMOSD, and MOGAD	28
Safety of potential breast milk exposure to IFN-β or glatiramer acetate	28
Tailoring B cell depletion therapy in MS according to memory B cell monitoring	28
Infliximab treatment in pathology-confirmed neurosarcoidosis	27
Clinical features of seronegative, but CSF antibody-positive, anti-NMDA receptor encephalitis	27
Longitudinally Extensive Myelitis Associated With Immune Checkpoint Inhibitors	27
COVID-19 Vaccination Reactogenicity in Persons With Multiple Sclerosis	27
Systemic Inflammation Is Associated With Neurologic Involvement in Pediatric Inflammatory Multisystem Syndrome Associated With SARS-CoV-2	27
Antiparanodal antibodies and IgG subclasses in acute autoimmune neuropathy	26
Ocrelizumab initiation in patients with MS	26
Prognostic Accuracy of NEDA-3 in Long-term Outcomes of Multiple Sclerosis	26
Telemedicine assessment of long-term cognitive and functional status in anti-leucine-rich, glioma-inactivated 1 encephalitis	26
Clinical and Laboratory Features in Anti-NF155 Autoimmune Nodopathy	26
Alemtuzumab therapy changes immunoglobulin levels in peripheral blood and CSF	26
Exercise Diminishes Plasma Neurofilament Light Chain and Reroutes the Kynurenine Pathway in Multiple Sclerosis	26
Insights into disseminated MS brain pathology with multimodal diffusion tensor and PET imaging	26
Kappa-Free Light Chains in CSF Predict Early Multiple Sclerosis Disease Activity	26
Cortical Thickness and Serum NfL Explain Cognitive Dysfunction in Newly Diagnosed Patients With Multiple Sclerosis	25
Long-term prognostic value of longitudinal measurements of blood neurofilament levels	25
Amyotrophic Lateral Sclerosis Survival Associates With Neutrophils in a Sex-specific Manner	25
High serum neurofilament associates with diffuse white matter damage in MS	25
Clostridium bolteae is elevated in neuromyelitis optica spectrum disorder in India and shares sequence similarity with AQP4	25
SARS-CoV-2 Infection in Multiple Sclerosis	25
Risk of MS relapse after yellow fever vaccination	25
Targeting B cells to modify MS, NMOSD, and MOGAD	24
Clinical and Radiologic Disease Activity in Pregnancy and Postpartum in MS	24
Rituximab-Induced Hypogammaglobulinemia and Infections in AQP4 and MOG Antibody–Associated Diseases	24
Updated Results of the COVID-19 in MS Global Data Sharing Initiative	24
Diffusion basis spectrum imaging provides insights into MS pathology	24
Neurosarcoidosis	24
Microglia as Central Protagonists in the Chronic Stress Response	24
Acute Inflammatory Diseases of the Central Nervous System After SARS-CoV-2 Vaccination	24
Thymoma and Autoimmune Encephalitis	24
Inflammatory and stress markers predicting pneumonia, outcome, and etiology in patients with stroke	24
Vaccine Hesitancy in Patients With Multiple Sclerosis	24
CSF microRNAs discriminate MS activity and share similarity to other neuroinflammatory disorders	23
Effects of Vitamin D and Body Mass Index on Disease Risk and Relapse Hazard in Multiple Sclerosis	23
Serum neurofilament light chain	23
Monitoring of radiologic disease activity by serum neurofilaments in MS	23
COVID-19 Infection in Fingolimod- or Siponimod-Treated Patients	23
Evaluation of Age-Dependent Immune Signatures in Patients With Multiple Sclerosis	23
Recovery From COVID-19 in Multiple Sclerosis	23
Increased HLA-DR expression and cortical demyelination in MS links with HLA-DR15	23
Aryl Hydrocarbon Receptor Activation in Astrocytes by Laquinimod Ameliorates Autoimmune Inflammation in the CNS	23
Interleukin-26, preferentially produced by T H 17 lymphocytes, regulates CNS barrier function	22
Dimethyl Fumarate Reduces Inflammation in Chronic Active Multiple Sclerosis Lesions	22
Toward Precision Phenotyping of Multiple Sclerosis	22
Diagnosis and Management of Opsoclonus-Myoclonus-Ataxia Syndrome in Children	22
CSF Findings in Acute NMDAR and LGI1 Antibody–Associated Autoimmune Encephalitis	22
Effect of the sphingosine-1-phosphate receptor modulator ozanimod on leukocyte subtypes in relapsing MS	22
Neuroprotective Properties of 4-Aminopyridine	22
Bickerstaff brainstem encephalitis with or without anti-GQ1b antibody	21
Imaging Characteristics of Choroid Plexuses in Presymptomatic Multiple Sclerosis	21
Clinical Features of COVID-19 on Patients With Neuromyelitis Optica Spectrum Disorders	21
Autoimmune Encephalitis Resembling Dementia Syndromes	21
Presence of SARS-CoV-2 Transcripts in the Choroid Plexus of MS and Non-MS Patients With COVID-19	21
Temporal Dynamics of MOG Antibodies in Children With Acquired Demyelinating Syndrome	21
Gut microbiota composition is associated with narcolepsy type 1	21
Intrathecal B-cell activation in LGI1 antibody encephalitis	21
Differential expression of the T-cell inhibitor TIGIT in glioblastoma and MS	21
CSF chitinase 3-like-1 association with disability of primary progressive MS	21
Chronic demyelination exacerbates neuroaxonal loss in patients with MS with unilateral optic neuritis	21
Increased Remyelination and Proregenerative Microglia Under Siponimod Therapy in Mechanistic Models	21

Brain amyloid in virally suppressed HIV-associated neurocognitive disorder	20
Neurological Autoimmunity Associated With Homer-3 Antibody	20
Primary Angiitis of the CNS	20
Guillain-Barré Syndrome Outbreak in Peru 2019 Associated With Campylobacter jejuni Infection	20
Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder	20
Heterogeneity of Acetylcholine Receptor Autoantibody–Mediated Complement Activity in Patients With Myasthenia Gravis	20
High-throughput investigation of molecular and cellular biomarkers in NMOSD	20
Abnormal B-Cell and Tfh-Cell Profiles in Patients With Parkinson Disease	20
Direct economic burden of patients with autoimmune encephalitis in western China	20
Serum neurofilament light chain and optical coherence tomography measures in MS	20
Ocrelizumab shorter infusion	20
B-Cell Compartmental Features and Molecular Basis for Therapy in Autoimmune Disease	20
RNA-binding protein altered expression and mislocalization in MS	20
Potential Role of CHI3L1+ Astrocytes in Progression in MS	20
Gut bacteria Akkermansia elicit a specific IgG response in CSF of patients with MS	20
Population-Based Epidemiology Study of Paraneoplastic Neurologic Syndromes	20
Clinically based score predicting cryptogenic NORSE at the early stage of status epilepticus	20
Encephalitis with radial perivascular emphasis	20
Predicting Aggressive Multiple Sclerosis With Intrathecal IgM Synthesis Among Patients With a Clinically Isolated Syndrome	20
Mesenchymal stem cell-derived neural progenitors in progressive MS	19
Pharmacodynamics of natalizumab extended interval dosing in MS	19
Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab	19
Human Herpesvirus 6 Encephalitis in Immunocompetent and Immunocompromised Hosts	19
Progranulin Suppressed Autoimmune Uveitis and Autoimmune Neuroinflammation by Inhibiting Th1/Th17 Cells and Promoting Treg Cells and M2 Macrophages	19
Anti-CD20 Disrupts Meningeal B-Cell Aggregates in a Model of Secondary Progressive Multiple Sclerosis	19
Is MS affecting the CNS only?	19
Disease activity in pregnancy and postpartum in women with MS who suspended rituximab and natalizumab	19
Interim Analysis of Pregnancy Outcomes After Exposure to Dimethyl Fumarate in a Prospective International Registry	19
Safety and Immune Effects of Blocking CD40 Ligand in Multiple Sclerosis	18
Genomic and serologic characterization of enterovirus A71 brainstem encephalitis	18
Intrathecal Antibody Production Against Epstein-Barr, Herpes Simplex, and Other Neurotropic Viruses in Autoimmune Encephalitis	18
Mass Cytometry of CSF Identifies an MS-Associated B-cell Population	18
Age-related visual dynamics in HIV-infected adults with cognitive impairment	18
Analysis of soluble interleukin-2 receptor as CSF biomarker for neurosarcoidosis	18
CSF Levels of CXCL12 and Osteopontin as Early Markers of Primary Progressive Multiple Sclerosis	18
CNS Lymphocytic Vasculitis in a Young Woman With COVID-19 Infection	18
Immune Skew of Circulating Follicular Helper T Cells Associates With Myasthenia Gravis Severity	18
Decrease in Serum Anti-MAG Autoantibodies Is Associated With Therapy Response in Patients With Anti-MAG Neuropathy	18
Investigating the Presence of Interattack Astrocyte Damage in Neuromyelitis Optica Spectrum Disorder	18
Covarying patterns of white matter lesions and cortical atrophy predict progression in early MS	18
T-Cell Specificity Influences Disease Heterogeneity in Multiple Sclerosis	18
Central Vein Sign Profile of Newly Developing Lesions in Multiple Sclerosis	17
Anti–Interleukin-6 and Janus Kinase Inhibitors for Severe Neurologic Toxicity of Checkpoint Inhibitors	17
Allogeneic BK Virus-Specific T-Cell Treatment in 2 Patients With Progressive Multifocal Leukoencephalopathy	17
Impact of treatment on cellular immunophenotype in MS	17
Role of Chitinase 3–like 1 as a Biomarker in Multiple Sclerosis	17
Association of intrathecal pleocytosis and IgG synthesis with axonal damage in early MS	17
Impact of Dietary Intervention on Serum Neurofilament Light Chain in Multiple Sclerosis	17
Acute necrotizing encephalopathy and myocarditis in a young patient with COVID-19	17
Anti-NMDAR Encephalitis in the Netherlands, Focusing on Late-Onset Patients and Antibody Test Accuracy	17
Ofatumumab Modulates Inflammatory T Cell Responses and Migratory Potential in Patients With Multiple Sclerosis	17
MRI Characteristics of Autoimmune Encephalitis With Autoantibodies to GABAA Receptor	17
COVID-19 in Patients With Neuromyelitis Optica Spectrum Disorders and Myelin Oligodendrocyte Glycoprotein Antibody Disease in North America	17
Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod	16
Chitinase 3–like 1 and neurofilament light chain in CSF and CNS atrophy in MS	16
Free light chains kappa can differentiate between myelitis and noninflammatory myelopathy	16
Lymphocyte recovery after fingolimod discontinuation in patients with MS	16
Use of Disease-Modifying Therapies in Pediatric Relapsing-Remitting Multiple Sclerosis in the United Kingdom	16
Anti-CD20 Depletes Meningeal B Cells but Does Not Halt the Formation of Meningeal Ectopic Lymphoid Tissue	16
Phenome-wide examination of comorbidity burden and multiple sclerosis disease severity	16
Baseline Microglial Activation Correlates With Brain Amyloidosis and Longitudinal Cognitive Decline in Alzheimer Disease	16
Diagnostic accuracy of intrathecal kappa free light chains compared with OCBs in MS	16
Placental transfer of NMDAR antibodies causes reversible alterations in mice	16
Optic Nerve Lesion Length at the Acute Phase of Optic Neuritis Is Predictive of Retinal Neuronal Loss	16
Neurofilament Light Chain Levels in Multiple Sclerosis Correlate With Lesions Containing Foamy Macrophages and With Acute Axonal Damage	16
Network Damage Predicts Clinical Worsening in Multiple Sclerosis	16
Epigallocatechin Gallate in Relapsing-Remitting Multiple Sclerosis	16
Demyelinating Events Following Initiation of Anti-TNFα Therapy in the British Society for Rheumatology Biologics Registry in Rheumatoid Arthritis	15
Humoral and Cellular Responses to SARS-CoV-2 in Convalescent COVID-19 Patients With Multiple Sclerosis	15
Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment	15
Molecular Level Characterization of Circulating Aquaporin-4 Antibodies in Neuromyelitis Optica Spectrum Disorder	15
Altered CSF Albumin Quotient Links Peripheral Inflammation and Brain Damage in MS	15
Absence of B Cells in Brainstem and White Matter Lesions Associates With Less Severe Disease and Absence of Oligoclonal Bands in MS	15
Evolution of Brain Volume Loss Rates in Early Stages of Multiple Sclerosis	15
Perturbed Microbiota/Immune Homeostasis in Multiple Sclerosis	15
Cell-Free DNA Derived From Neutrophils Triggers Type 1 Interferon Signature in Neuromyelitis Optica Spectrum Disorder	15
Paraneoplastic Cerebellar Degeneration	15
Immune Response and Safety of SARS-CoV-2 mRNA-1273 Vaccine in Patients With Myasthenia Gravis	15
Validation of the NEOS score in Chinese patients with anti-NMDAR encephalitis	15
Sustained Low Relapse Rate With Highly Variable B-Cell Repopulation Dynamics With Extended Rituximab Dosing Intervals in Multiple Sclerosis	15
Contactin-1 autoimmunity	15
Anti-Hu Antibodies in Patients With Neurologic Side Effects of Immune Checkpoint Inhibitors	15
CSF SERPINA3 Levels Are Elevated in Patients With Progressive MS	14
Mitigating alemtuzumab-associated autoimmunity in MS	14
High incidence and prevalence of MS in Møre and Romsdal County, Norway, 1950–2018	14
Aryl Hydrocarbon Receptor Plasma Agonist Activity Correlates With Disease Activity in Progressive MS	14
Differential Binding of Autoantibodies to MOG Isoforms in Inflammatory Demyelinating Diseases	14
Multiple Sclerosis	14
Assessing Neurofilaments as Biomarkers of Neuroprotection in Progressive Multiple Sclerosis	14
Autoimmunity complicating SARS-CoV-2 infection in selective IgA-deficiency	14
Dimethyl Fumarate Treatment in Patients With Primary Progressive Multiple Sclerosis	14
Antibodies to nodal/paranodal proteins in paediatric immune-mediated neuropathy	14
CSF Chitinase 3–Like 2 Is Associated With Long-term Disability Progression in Patients With Progressive Multiple Sclerosis	14
Wearing-off at the end of natalizumab dosing intervals is associated with low receptor occupancy	13
Relapse recovery	13